
Opinion|Videos|January 20, 2025
Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes
Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
A Look at Lynkuet® (Elinzanetant) for the Treatment of Moderate to Severe Vasomotor Symptoms
2
Facility-Based CRC Screening Nearly 10-Fold Higher in 45- to 49-Year-Olds After Guideline Changes
3
Nonstimulant Pharmacotherapy for ADHD: A Clinical Update for Primary Care
4
FDA Approves New Treatment for Acromegaly: Daily Dose
5

































































































































































































































































































